Institutional members access full text with Ovid®

Share this article on:

Prevalence of Cryptosporidium Carriage and Disease in Children With Primary Immune Deficiencies Undergoing Hematopoietic Stem Cell Transplant in Northern Europe

Davies, Angharad P. PhD*†; Slatter, Mary MD; Gennery, Andrew R. MD‡§; Robinson, Guy PhD; Crouch, Nigel BSc; Elwin, Kristin PhD; Hadfield, Stephen J. PhD; Cant, Andrew J. MD‡§; Davies, E. Graham MA, MB, BChir; Chalmers, Rachel M. PhD*†

Pediatric Infectious Disease Journal: May 2017 - Volume 36 - Issue 5 - p 504–506
doi: 10.1097/INF.0000000000001517
Immunology Reports

A prospective cohort study of children with primary immunodeficiencies undergoing hematopoietic stem cell transplant in the United Kingdom investigated the extent and significance of Cryptosporidium carriage in this high risk group. Three of 42 children recruited were infected with Cryptosporidium, a lower proportion than previously described. One had serious disease. The underlying immunodeficiency likely had a bearing on the clinical presentation and possible outcome of infection.

From the *Swansea University Medical School, Singleton Park, Swansea, United Kingdom; Cryptosporidium Reference Unit, Public Health Wales Microbiology Swansea, Singleton Hospital, Sketty Lane, Swansea, United Kingdom; Paediatric Immunology Department, Great North Children’s Hospital, Queen Victoria Road, Newcastle upon Tyne, United Kingdom; §Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; and Centre for Immunodeficiency, Institute of Child Health, University College London and Great Ormond Street Hospital, London, United Kingdom.

Accepted for publication September 29, 2016.

This study used IMS (Isolate, TCS Biosciences; Crypto-Cel, Cellabs). This is an in vitro device for the separation of Cryptosporidium oocysts from environmental samples, particularly water. However, it has been validated previously for use with fecal specimens (Robinson et al). The authors have no other conflicts of interest to disclose.

This study was carried out with the ethical approval of the relevant UK NHS Research Ethics Committee and all required NHS R&D permissions. Informed consent was obtained from all individual participants included in the study and/or their guardians.

Address for correspondence: Angharad P. Davies, MA, MB, BChir, Swansea University Medical School, Singleton Park, Swansea, United Kingdom. E-mail: angharad.p.davies@swansea.ac.uk.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.